Canada - Engels - Health Canada

allergan inc - ulipristal acetate - tablet - 5mg - ulipristal acetate 5mg - contraceptives

Israël - Engels - Ministry of Health

cts ltd - ulipristal acetate - tablets - ulipristal acetate 5 mg - ulipristal - pre operative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.

Singapore - Engels - HSA (Health Sciences Authority)

hyphens pharma pte. ltd. - ulipristal acetate - tablet - 30.00 mg - ulipristal acetate 30.00 mg

Singapore - Engels - HSA (Health Sciences Authority)

zuellig pharma pte. ltd. - ulipristal acetate micronized - tablet - 5.00mg - ulipristal acetate micronized 5.00mg

Verenigd Koninkrijk - Engels - MHRA (Medicines & Healthcare Products Regulatory Agency)

hra pharma uk ltd - ulipristal acetate - tablet - 30mg

Verenigd Koninkrijk - Engels - MHRA (Medicines & Healthcare Products Regulatory Agency)

gedeon richter (uk - ulipristal acetate - tablet - 5mg

Maleisië - Engels - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

hyphens pharma sdn. bhd. - ulipristal acetate; ulipristal acetate -

Maleisië - Engels - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

zuellig pharma sdn bhd - ulipristal acetate -

Verenigde Staten - Engels - NLM (National Library of Medicine)

rpk pharmaceuticals, inc. - ulipristal acetate (unii: yf7v70n02b) (ulipristal - unii:6j5j15q2x8) - ella is a progesterone agonist/antagonist emergency contraceptive indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure. ella is not intended for routine use as a contraceptive. ella is contraindicated for use in the case of known or suspected pregnancy. [see use in specific populations (8.1 ).] risk summary ella is contraindicated for use during an existing or suspected pregnancy. no signal of concern regarding pregnancy complications was found in postmarketing studies [see data ]. isolated cases of major malformations in ella- exposed pregnancies were identified; however, the data are not sufficient to determine a risk for birth defects with inadvertent use of ella during pregnancy. miscarriage was reported in 14% of the known pregnancy outcomes; a rate that is similar to the u.s background rate for miscarriage. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized p

Verenigde Staten - Engels - NLM (National Library of Medicine)

a-s medication solutions - ulipristal acetate (unii: yf7v70n02b) (ulipristal - unii:6j5j15q2x8) - ella is a progesterone agonist/antagonist emergency contraceptive indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure. ella is not intended for routine use as a contraceptive. ella is contraindicated for use in the case of known or suspected pregnancy. [see use in specific populations (8.1 ).] risk summary ella is contraindicated for use during an existing or suspected pregnancy. no signal of concern regarding pregnancy complications was found in postmarketing studies [see data ]. isolated cases of major malformations in ella- exposed pregnancies were identified; however, the data are not sufficient to determine a risk for birth defects with inadvertent use of ella during pregnancy. miscarriage was reported in 14% of the known pregnancy outcomes; a rate that is similar to the u.s background rate for miscarriage. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized p